1. Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors. (14th November 2016) Authors: Ahamadi, M; Freshwater, T; Prohn, M; Li, CH; de Alwis, DP; de Greef, R; Elassaiss‐Schaap, J; Kondic, A; Stone, JA Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 6:Number 1(2017) Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose‐Range Selection of the Anti–PD‐1 Antibody Pembrolizumab. (8th November 2016) Authors: Lindauer, A; Valiathan, CR; Mehta, K; Sriram, V; de Greef, R; Elassaiss‐Schaap, J; de Alwis, DP Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 6:Number 1(2017) Page Start: 11 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma. (29th November 2016) Authors: Chatterjee, MS; Elassaiss‐Schaap, J; Lindauer, A; Turner, DC; Sostelly, A; Freshwater, T; Mayawala, K; Ahamadi, M; Stone, JA; de Greef, R; Kondic, AG; de Alwis, DP Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 6:Number 1(2017) Page Start: 29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pembrolizumab: Role of Modeling and Simulation in Bringing a Novel Immunotherapy to Patients With Melanoma. (5th November 2016) Authors: de Greef, R; Elassaiss‐Schaap, J; Chatterjee, M; Turner, DC; Ahamadi, M; Forman, M; Cutler, D; de Alwis, DP; Kondic, A; Stone, J Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 6:Number 1(2017) Page Start: 5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Using Model‐Based "Learn and Confirm" to Reveal the Pharmacokinetics‐Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE‐001 Trial. (8th November 2016) Authors: Elassaiss‐Schaap, J; Rossenu, S; Lindauer, A; Kang, SP; de Greef, R; Sachs, JR; de Alwis, DP Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 6:Number 1(2017) Page Start: 21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗